Isomorphic Labs raises $5bn to accelerate AI drug discovery
The Alphabet-backed company is securing massive funding to move its AI-designed drugs into clinical trials by 2026.
The short version
- Isomorphic Labs raised $5bn in a Series C round co-led by Greenoaks and Sequoia Capital.
- The company aims to produce hundreds of drugs per year using its IsoDDE drug design engine.
- Isomorphic expects to begin its first clinical trials by the end of 2026.
- The funding will allow the company to expand from small-molecule drugs to large-molecule biologics.
- The company currently has more than 20 programs underway with partners like Eli Lilly and Novartis.
Why it matters
This investment signals a massive bet on AI's ability to shorten the timeline for creating new medicines. If successful, it could shift the pharmaceutical industry from a trial-and-error model to a predictive, data-driven one.
A massive capital injection
Isomorphic Labs recently secured $5bn in a Series C funding round to accelerate its work in AI-driven drug discovery. The round was co-led by prominent investors Greenoaks and Sequoia Capital, with participation from Andreessen Horowitz and several other new backers. This follows a $2.1bn round the company raised in May of this year.
The investment came with continued significant backing from Alphabet, the parent company of Google. While the company did not officially disclose its valuation, reports from Bloomberg suggest the round values Isomorphic at approximately $50bn. This funding marks a major milestone for the company since Demis Hassabis stepped back as the chief executive of Google DeepMind in August.
Existing investors also participated in the oversubscribed round, including Thrive Capital, MGX, GV, CapitalG, Temasek, and the UK Sovereign AI Fund. These backers are betting on the company's ability to build foundational technology for the future of medicine. The capital is intended to help the company scale its operations and move toward human clinical trials.
Scaling the drug design engine
At the heart of Isomorphic Labs is its drug design engine, known as IsoDDE. This technology is currently producing positive preclinical results in various programs focused on immunology and oncology. The company is leveraging these models to develop new treatments in partnership with major pharmaceutical firms like Johnson & Johnson, Novartis, and Eli Lilly.
The company is currently managing more than 20 different programs simultaneously. Demis Hassabis, who serves as the company's chief executive, stated that the goal is to build a platform capable of producing hundreds of drugs every year. This high-volume output is a significant shift from traditional drug development, which often takes years to produce a single candidate.
Sequoia Capital noted that Isomorphic has successfully identified scaling laws for its models. In the context of AI, scaling laws mean that the performance of the models continues to improve as the company provides them with more data and more computing power. This suggests that the company's technology is designed to get smarter and more accurate as it grows.
Expanding medical modalities
While many AI drug discovery efforts focus on small-molecule drugs, Isomorphic Labs plans to use this new funding to broaden its scope. Hassabis indicated that the company intends to move into "pretty much all modalities." This includes large-molecule biologics, which are complex medicines derived from living organisms rather than simple chemical compounds.
By expanding into biologics, the company aims to address a wider range of diseases that are difficult to treat with standard chemistry. The goal is to create a versatile platform that can handle various types of biological targets. This expansion is a key part of the company's strategy to become a comprehensive leader in AI-assisted medicine.
The company is currently on track with its regulatory submissions for its various programs. While no regulator has yet approved a drug designed entirely by AI, Isomorphic expects to have more news to share regarding these milestones in 2027. The company remains focused on navigating the complex legal and safety requirements of the pharmaceutical industry.
Infrastructure and leadership
Despite concerns in the tech industry regarding the availability of AI chips, Isomorphic Labs maintains a stable position. Because Google designs its own AI chips, the company can rely on secure compute pipelines to train its models. This internal infrastructure helps insulate the company from some of the supply chain worries affecting other AI firms.
The leadership structure of the company has also seen recent shifts. Demis Hassabis transitioned from his role as chief executive of Google DeepMind to become the chair of DeepMind and the chief scientist of Alphabet. However, he remains the chief executive of Isomorphic Labs, providing continuity for the drug discovery project.
Isomorphic Labs was founded in 2021 to build upon the AlphaFold protein structure model developed by Google DeepMind. The company maintains a global presence with its headquarters in London and additional offices in Lausanne and Cambridge, Massachusetts. These locations serve as hubs for the research and development of its AI-driven medical technologies.
What to watch
- Whether Isomorphic Labs successfully reaches its goal of starting clinical trials by the end of 2026.
- The first instance of an AI-designed drug receiving regulatory approval from a government body.
- How the company's expansion into large-molecule biologics affects its partnership agreements.
Sources and links
- ReportingThe Next Web: the article we sourced
First reported by The Next Web. Written by the SI Agent News Desk from the reporting above.Written with AI from the source above. Every number is checked against the source. Spot a mistake? Corrections.
Liked it? Say why
Add a line for other readers.
No account needed. We never show your email. Comments with links, ads or abuse are held and not shown. Your comment shows after a quick check.